Zacks: Brokerages Expect Natus Medical Inc (BABY) to Post $0.24 EPS

Wall Street analysts expect that Natus Medical Inc (NASDAQ:BABY) will report earnings of $0.24 per share for the current fiscal quarter, according to Zacks. Three analysts have issued estimates for Natus Medical’s earnings. The highest EPS estimate is $0.25 and the lowest is $0.24. Natus Medical reported earnings per share of $0.30 in the same quarter last year, which suggests a negative year-over-year growth rate of 20%. The company is expected to report its next earnings report before the market opens on Wednesday, April 25th.

According to Zacks, analysts expect that Natus Medical will report full-year earnings of $1.63 per share for the current year, with EPS estimates ranging from $1.62 to $1.63. For the next financial year, analysts expect that the company will post earnings of $1.92 per share, with EPS estimates ranging from $1.84 to $2.00. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side analysts that follow Natus Medical.

How to Become a New Pot Stock Millionaire

Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, February 7th. The medical equipment provider reported $0.42 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.54 by ($0.12). Natus Medical had a positive return on equity of 11.36% and a negative net margin of 4.05%. The firm had revenue of $131.40 million during the quarter, compared to the consensus estimate of $131.38 million. During the same quarter in the prior year, the business posted $0.51 EPS. The firm’s revenue for the quarter was up 22.0% on a year-over-year basis.

BABY has been the topic of several recent analyst reports. BidaskClub cut shares of Natus Medical from a “sell” rating to a “strong sell” rating in a report on Saturday, January 6th. Zacks Investment Research cut shares of Natus Medical from a “hold” rating to a “strong sell” rating in a report on Thursday, January 11th. Benchmark reiterated a “buy” rating and issued a $49.00 price target (down previously from $55.00) on shares of Natus Medical in a report on Tuesday, January 16th. William Blair cut shares of Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Finally, Roth Capital set a $39.00 price target on shares of Natus Medical and gave the company a “buy” rating in a report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $44.33.

In related news, Director Ken Ludlum sold 4,000 shares of Natus Medical stock in a transaction on Friday, March 2nd. The shares were sold at an average price of $31.68, for a total value of $126,720.00. Following the sale, the director now owns 93,825 shares in the company, valued at $2,972,376. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.50% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in BABY. BNP Paribas Arbitrage SA boosted its holdings in Natus Medical by 54.4% in the third quarter. BNP Paribas Arbitrage SA now owns 17,245 shares of the medical equipment provider’s stock valued at $647,000 after acquiring an additional 6,073 shares in the last quarter. Sei Investments Co. boosted its holdings in Natus Medical by 149.9% in the third quarter. Sei Investments Co. now owns 7,952 shares of the medical equipment provider’s stock valued at $298,000 after acquiring an additional 4,770 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its holdings in Natus Medical by 60.1% in the third quarter. Municipal Employees Retirement System of Michigan now owns 12,420 shares of the medical equipment provider’s stock valued at $466,000 after acquiring an additional 4,660 shares in the last quarter. Rhumbline Advisers boosted its holdings in shares of Natus Medical by 2.5% during the 3rd quarter. Rhumbline Advisers now owns 67,065 shares of the medical equipment provider’s stock valued at $2,515,000 after buying an additional 1,620 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in shares of Natus Medical during the 3rd quarter valued at $138,000. Institutional investors and hedge funds own 95.96% of the company’s stock.

Shares of Natus Medical stock traded down $1.00 on Friday, hitting $32.80. The stock had a trading volume of 358,046 shares, compared to its average volume of 562,151. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.54 and a current ratio of 3.32. Natus Medical has a one year low of $28.00 and a one year high of $43.60. The stock has a market capitalization of $1,107.56, a price-to-earnings ratio of 22.62 and a beta of 0.47.

Natus Medical announced that its board has authorized a stock repurchase plan on Thursday, February 22nd that authorizes the company to repurchase $30.00 million in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s leadership believes its stock is undervalued.

ILLEGAL ACTIVITY WARNING: “Zacks: Brokerages Expect Natus Medical Inc (BABY) to Post $0.24 EPS” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3336157/zacks-brokerages-expect-natus-medical-inc-baby-to-post-0-24-eps.html.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Get a free copy of the Zacks research report on Natus Medical (BABY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

EnPro Industries  Downgraded by Zacks Investment Research to “Sell”
EnPro Industries Downgraded by Zacks Investment Research to “Sell”
Essendant  Stock Rating Upgraded by BidaskClub
Essendant Stock Rating Upgraded by BidaskClub
Innospec  Upgraded to “Buy” at BidaskClub
Innospec Upgraded to “Buy” at BidaskClub
Motorcar Parts of America  Stock Rating Lowered by BidaskClub
Motorcar Parts of America Stock Rating Lowered by BidaskClub
Lennar Co.  Announces $0.04 Quarterly Dividend
Lennar Co. Announces $0.04 Quarterly Dividend
Q2  Reaches New 12-Month High and Low at $48.92
Q2 Reaches New 12-Month High and Low at $48.92


Leave a Reply

© 2006-2018 Ticker Report. Google+.